Summary
Multiple grapefruit–atorvastatin interaction details in the provided statements are not supported as written by the supplied label excerpts (e.g., enzyme binding mechanism, “even small amounts,” and specific symptom/toxicity associations). Several interaction-related points are also overstated beyond label language (e.g., toxicity/organ-specific effects).
Category Scores
Accurate Statements
Grapefruit contains a compound called furanocoumarin.
Furanocoumarin can inhibit the metabolism of certain medications, including Lipitor (atorvastatin).
Grapefruit can increase Lipitor levels in the bloodstream.
Label 7.2: “Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin…”
Increased Lipitor levels can lead to increased risk of toxicity.
Grapefruit can slow Lipitor metabolism by binding to liver enzymes responsible for breaking down Lipitor.
Consuming grapefruit or grapefruit products (including juice, segments, and flavorings) is recommended to be avoided while taking Lipitor.
Increased Lipitor levels can lead to increased side effects.
Unsupported Statements
Grapefruit contains a compound called furanocoumarin.
Not supported by the supplied label excerpt(s). Supplied label only states grapefruit contains components that inhibit CYP 3A4.
Furanocoumarin can inhibit the metabolism of certain medications, including Lipitor (atorvastatin).
The label excerpt attributes effect to components that inhibit CYP 3A4; it does not mention furanocoumarin or that specific mechanism wording.
Increased Lipitor levels can lead to increased side effects.
The label excerpt does not link grapefruit-induced concentration increases to side effects.
Increased Lipitor levels can lead to increased risk of toxicity.
The label excerpt does not provide that causal linkage for grapefruit.
Grapefruit can slow Lipitor metabolism by binding to liver enzymes responsible for breaking down Lipitor.
The label excerpt says grapefruit components inhibit CYP 3A4; it does not describe grapefruit binding to “liver enzymes responsible for breaking down Lipitor.”
Grapefruit interactions with Lipitor can increase the risk of side effects such as muscle weakness.
The supplied label excerpt does not mention muscle weakness specifically in the grapefruit context; it discusses myopathy/rhabdomyolysis risk with certain drugs/doses.
Grapefruit interactions with Lipitor can increase the risk of side effects such as liver damage.
No grapefruit-specific liver damage statement is present in the supplied label excerpt.
Grapefruit interactions with Lipitor can increase the risk of side effects such as kidney problems.
The supplied label excerpt does not link grapefruit to kidney problems.
Grapefruit interactions with Lipitor can increase the risk of toxicity with symptoms such as nausea.
The supplied label excerpt does not associate grapefruit–atorvastatin interaction with toxicity symptoms like nausea.
Grapefruit interactions with Lipitor can increase the risk of toxicity with symptoms such as vomiting.
The supplied label excerpt does not associate grapefruit–atorvastatin interaction with vomiting.
Grapefruit interactions with Lipitor can increase the risk of toxicity with symptoms such as abdominal pain.
The supplied label excerpt does not associate grapefruit–atorvastatin interaction with abdominal pain.
Grapefruit interactions with Lipitor can reduce the effectiveness of Lipitor at lowering cholesterol levels.
The supplied label excerpt discusses increased plasma concentrations; it does not state reduced efficacy.
Older adults may be more susceptible to grapefruit interactions with Lipitor.
No age-based susceptibility statement appears in the supplied label excerpts.
People with pre-existing liver or kidney disease may be more susceptible to grapefruit interactions with Lipitor.
No such grapefruit-specific susceptibility statement appears in the supplied label excerpts.
People taking other medications that are metabolized by the same enzymes as Lipitor may be at increased risk of interactions.
The label excerpt provides a general CYP3A4/myopathy interaction risk statement, but does not specifically state grapefruit interactions; and the statement is too broad relative to provided text.
Consuming grapefruit or grapefruit products (including juice, segments, and flavorings) is recommended to be avoided while taking Lipitor.
The label excerpt does not provide an avoidance recommendation or specify “segments”/“flavorings.” It only notes increased concentrations especially with excessive consumption.
Even small amounts of grapefruit can interact with Lipitor.
The label excerpt specifies increased plasma concentrations “especially with excessive grapefruit juice consumption (>1.2 liters per day),” which does not support a “small amounts” statement.
Contradictions
Low
AI Statement
Consuming grapefruit or grapefruit products (including juice, segments, and flavorings) is recommended to be avoided while taking Lipitor.
Label Reference
Label 7.2: “can increase plasma concentrations… especially with excessive grapefruit juice consumption (>1.2 liters per day).”
Important Omissions
The provided statements do not include the label’s quantitative detail that the increase is especially associated with excessive grapefruit juice consumption (>1.2 liters per day).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The label supports a grapefruit–CYP3A4–increased atorvastatin plasma concentration interaction, but the statements add many unsupported, specific toxicity/symptom and organ-effect claims and omit the label’s “especially with excessive” qualifier; this could mislead risk perception and behavior beyond what the label excerpts support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most grapefruit interaction statements (mechanism wording, avoidance guidance, “even small amounts,” and specific side-effect/toxicity symptom/organ claims) are not supported by the supplied label excerpts; only the general increased plasma concentration via CYP3A4 inhibition is supported.
Suggested Improvement
Limit grapefruit interaction description to the label-supported statement: grapefruit components inhibit CYP 3A4 and can increase atorvastatin plasma concentrations, especially with excessive grapefruit juice consumption (>1.2 liters per day); remove unsupported claims about furanocoumarin, binding to liver enzymes, organ-specific toxicity, symptom examples, and “avoid all grapefruit/any small amount.”